Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 68, Issue 12, Pages 2857-2866
Publisher
Wiley
Online
2016-07-07
DOI
10.1002/art.39808
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies
- (2016) P Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects
- (2014) J. Voss et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
- (2013) Tom W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
- (2013) John D Isaacs et al. ARTHRITIS RESEARCH & THERAPY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Role of Interleukin-6 in the Anemia of Chronic Disease
- (2008) Dominic S.C. Raj SEMINARS IN ARTHRITIS AND RHEUMATISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now